A

Anavex Life Sciences Corp
D

AVXL

8.34000
USD
-0.35
(-4.03%)
مغلق
حجم التداول
30,168
الربح لكل سهم
-1
العائد الربحي
-
P/E
-15
حجم السوق
709,435,420
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    AMGN
    AMGN
    5.10
    (1.71%)
    303.15 USD
    BIIB
    BIIB
    3.560
    (2.60%)
    140.630 USD
    GILD
    GILD
    -0.140
    (-0.13%)
    109.920 USD
    I
    INCY
    0.790
    (1.11%)
    72.150 USD
    LLY
    LLY
    0.67
    (0.08%)
    874.04 USD
    MRK
    MRK
    1.820
    (2.08%)
    89.500 USD
    P
    PBYI
    -0.01500
    (-0.51%)
    2.90500 USD
    PFE
    PFE
    0.405
    (1.56%)
    26.305 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    S
    SAGE
    0.16000
    (2.24%)
    7.30500 USD
    المزيد
الأخبار
المقالات

العنوان: Anavex Life Sciences Corp

القطاع: Healthcare
الصناعة: Biotechnology
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.